399 related articles for article (PubMed ID: 23873764)
1. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
5. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
6. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
[TBL] [Abstract][Full Text] [Related]
8. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
9. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
10. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
11. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
13. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
Berry K; Ioannou GN
Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
[TBL] [Abstract][Full Text] [Related]
14. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
Na GH; Kim EY; Hong TH; You YK; Kim DG
HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
[TBL] [Abstract][Full Text] [Related]
15. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
Sharr WW; Chan SC; Lo CM
Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
[TBL] [Abstract][Full Text] [Related]
16. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
17. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
18. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
19. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
20. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation.
Lai Q; Avolio AW; Manzia TM; Sorge R; Agnes S; Tisone G; Berloco PB; Rossi M
Clin Transplant; 2012; 26(2):E125-31. PubMed ID: 22192083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]